Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...
Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% ...
BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...
Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its technological innovations and diversification plans regarding its product portfolio. The optimism, led by a solid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback